Report Overview

The increasing prevalence of cancer, advancements in diagnostic technologies, and the proactive efforts of both private and public organizations are expected to drive the growth of the North America cancer Biopsy market during the forecast period between 2024 and 2030.

North America Cancer Biopsy Market – Industry Trends & Forecast Report, 2030

The North America Cancer Biopsy Market size was estimated at USD 10.34 Billion in 2023. During the forecast period between 2024 and 2030, the North America Cancer Biopsy Market size is projected to grow at a CAGR of 9.77% reaching a value of USD 22.87 Billion by 2030. The North America cancer Biopsy market is experiencing substantial growth, propelled by factors such as the increasing prevalence of cancer, advancements in diagnostic technologies, and the proactive efforts of both private and public organizations. According to data provided by the Association of Community Cancer Centers, the trajectory of this growth is further underscored by the implementation of the Cancer Patient Equity Act in 2022, following its introduction in 2021. This legislation aims to extend coverage for specific cancer diagnostic and laboratory tests under the purview of Medicare, Medicaid, and the Children's Health Insurance Program. Notably, the bill underscores the importance of molecular testing at the time of cancer diagnosis, advocating for its inclusion within the ambit of healthcare coverage. Additionally, the Cancer Patient Equity Act seeks to spearhead an educational and awareness initiative, collaborating with the Department of Health and Human Services and the director of the National Human Genome Research Institute. This program is designed to spread knowledge about genomic testing, clarify its applications, and highlight the pivotal role played by genetic counselors in this domain. The confluence of these factors suggests a comprehensive and forward-looking approach to addressing the evolving landscape of cancer Biopsy in North America.

Cancer Biopsy – Overview

Cancer Biopsy refers to the methods and techniques employed to detect and identify the presence of cancer in an individual. The goal of cancer Biopsy is to identify abnormalities in cells or tissues that may indicate the development of cancerous growths. These diagnostic methods encompass a wide range of approaches, including medical imaging, laboratory tests, and molecular analysis. Common diagnostic tools include X-rays, CT scans, MRIs, biopsies, blood tests, and genetic testing. Early and accurate detection of cancer is crucial for effective treatment and improved prognosis. Advancements in technology and research have led to the development of more precise and personalized diagnostic methods, enhancing the ability to detect cancer at earlier stages and tailor treatment plans to individual patients. Cancer Biopsy play a pivotal role in the overall management of cancer, facilitating timely interventions and contributing to better outcomes for patients.

North America Cancer Biopsy Market

Growth Drivers

Rising Cancer Incidence

The North America cancer Biopsy market is anticipated to witness substantial growth, primarily fueled by the escalating cancer incidence in the United States in the projected period. According to the 2024 data from John Wiley & Sons, Inc., The American Cancer Society projects an alarming number of new cancer cases and deaths in the United States. According to their estimates, 2,001,140 new cancer cases and 611,720 cancer-related deaths are expected in 2024. This data underscores the pressing need for advanced and efficient cancer Biopsy tools and technologies to manage the rising burden of cancer in the Country. The statistics highlight the important role of accurate and timely diagnosis in managing the disease, driving the demand for innovative diagnostic solutions. This surge in cancer cases is expected to be a main driver for the growth of the North America cancer Biopsy market, as healthcare providers and researchers seek innovative solutions to enhance early detection, prognosis, and treatment outcomes in the face of this escalating health crisis.

Challenges

Technological Complexity

Addressing public concerns and misinformation surrounding new technologies poses a significant challenge to the growth of the North American cancer Biopsy market. Despite remarkable advancements in diagnostic tools and methodologies with the potential to revolutionize cancer detection and treatment, their effectiveness is hindered by a lack of public understanding and trust. Widespread misinformation about the safety, accuracy, and potential side effects of emerging diagnostic technologies creates doubt among both patients and healthcare providers. The prevalence of unproven interventions and misinformation contributes to the preference for unverified treatments over evidence-based, effective ones. This situation is particularly precarious given the complexity of cancer and the varying responses to interventions across tissue types and individuals. Additionally, people with cancer are particularly vulnerable to misinformation due to the psychological distress that often accompanies a cancer diagnosis. The growing prevalence of cancer misinformation is a microcosm of the wider problem of scientific misinformation, and it remains poorly understood by the public despite its ubiquity. These concerns and misinformation can impede the adoption of new cancer diagnostic technologies, despite the significant growth and demand in cancer Biopsy in North America

Impact of Escalating Geopolitical Tensions on the North America Cancer Biopsy Market

Geopolitical tensions can impact the North America cancer Biopsy market in various ways. The increasing geopolitical conflicts may disrupt the overall growth of the North America cancer Biopsy market, specifically impacting segments like colorectal cancer screening and Biopsy. External factors, such as geopolitical tensions, can introduce risks and uncertainties into the next-generation cancer Biopsy market in North America, influencing its dynamics and posing challenges for stakeholders. Despite these obstacles, the oncology biomarkers market is expected to experience growth, driven by the implementation of innovative technologies for enhanced cancer detection, prognosis, and treatment effectiveness, showcasing the market's ability to adapt to dynamic conditions. The biotechnology sector, including cancer Biopsy, faces concerns about the impact of geopolitical tensions, as political risks can compromise the sector's resilience in the face of uncertainties. The North America region currently holds a dominant position in the global colorectal cancer screening and diagnostic market, mainly due to the increasing incidence of the disease. Therefore, geopolitical tensions have the potential to exert far-reaching effects on the cancer Biopsy market in North America, influencing its overall growth and operational dynamics.

North America Cancer Biopsy Market

Segmental Coverage

North America Cancer Biopsy Market – By Product

Based on type, the North America cancer Biopsy market is segmented into instruments, kits and consumables and services. The kits and consumables segment dominated the cancer biopsy market. This can be attributed to the critical function these components play in the biopsy process. Biopsy kits and consumables, such as needles and reagents, are essential for collecting and analyzing tissue samples, resulting in precise cancer diagnosis. Large investments by major industry players have considerably assisted the segment's growth. The widespread availability of technologically advanced instruments, as well as the highly developed healthcare systems in the United States and Canada, contribute to this segment's significant presence in North America.     

North America Cancer Biopsy Market – By Type

Based on type, the North America cancer Biopsy market is segmented into tissue biopsy, surgical biopsy, liquid biopsy, and others. During the forecast period, the liquid biopsy segment is anticipated to hold a significant market share. Liquid biopsies have revolutionized clinical oncology by providing a minimally invasive tool for tumor identification, screening, early detection of recurrence, and personalized treatment regimens. The advantages of liquid biopsy, such as lower costs, early prognosis, therapy monitoring, and patient comfort, have greatly improved its adoption and market share. Furthermore, the increased use of liquid biopsies in the United States, as well as ongoing innovations in biopsy procedures, have led to the liquid biopsy segment's market domination. For instance, Illumina Inc., a global pioneer in DNA sequencing and array-based technologies, released a new iteration of their distributed liquid biopsy assay for genomic profiling. The TruSight™ Oncology 500 ctDNA v2 (TSO 500 ctDNA v2) is a research assay that offers noninvasive comprehensive genomic profiling (CGP) of circulating tumour DNA (ctDNA) from blood when tissue testing is not available, or to supplement tissue-based testing.

North America Cancer Biopsy Market – By Country

The in-depth research report on the North America cancer Biopsy market covers countries of the United States and Canada. The United States is expected to dominate the North America cancer Biopsy market due to the high prevalence of cancer, technological improvements, increasing incidence of cancer, and growing awareness regarding early diagnosis. In the United States, the University of Chicago Medicine is advancing cancer diagnostics with a liquid biopsy, offering a novel approach to identifying and monitoring cancer.

Competitive Landscape

Major players operating in the North America Cancer Biopsy Market include lllumina Inc, BD (Becton, Dickinson and Company), Myriad Genetics Inc., Thermo Fisher Scientific, BIOCEPT INC., Hologic Inc, Danaher, Agilent Technologies Inc., IZI Medical, Johnson & Johnson Services, Inc., Medtronic, Boston Scientific Corporation, CONMED Corporation, INRAD, Inc.. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

Recent Developments

• In October 2023 - DELFI Biopsy, Inc., a provider of user-friendly blood-based tests that provide a new way to improve cancer detection, announced the initial commercial availability of FirstLook Lung. FirstLook is a blood test that determines the possibility of detecting lung cancer using low-dose CT (LDCT) and has a negative predictive value (NPV) of 99.7%.
• In July 2023 - Quest Biopsy, the leading provider of diagnostic information services, announced the launch of an innovative prostate cancer biomarker test through its subspecialty pathology business, AmeriPath, in conjunction with Envision Sciences. Envision Sciences Pty Ltd. is an Australian clinical Biopsy firm working on a pipeline of biomarker-based cancer diagnostic and predictive assays for tissue and blood.

Scope of the Report

By Product

• Instruments  

• Kits and Consumables  

• Services

By Type

• Tissue Biopsy  

• Surgical Biopsy  

• Liquid Biopsy  

• Others

By Application

• Breast Cancer  

• Colorectal Cancer  

• Cervical Cancer 

• Lung Cancers  

• Others (Including Liver Cancer, Blood Cancer, Prostate Cancer etc.)

By End User

• Hospitals

• Diagnostic Laboratories

• Others

By Country

• United States

• Canada